Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
QLG2198 (Difelikefalin) in Hemodialysis Patients with Moderate-to-Severe Pruritus
NCT06446310Phase 3Recruiting
- Sponsor
- Qilu Pharmaceutical
- Start
- Jun 2024
- Primary completion
- Feb 2025
- Modality
- Peptides, Small Molecules
- Countries
- 1
01
Overview
A Phase 3 trial of difelikefalin in uremic pruritus, sponsored by Qilu Pharmaceutical. Started Jun 2024; status: recruiting.
02
Drugs
difelikefalin
03
Conditions
uremic pruritus
Beyond the preview
Go deeper on NCT06446310.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06446310.